“Requip CR did not make it to market. Why? Not because it’s not safe. Not because it’s not efficacious. The FDA said, ‘Yeah, you’ve got all that. But tell me why you’re better than [Requip].’ Well, that was an unprecedented question from the FDA.”
Chris Viehbacher, president of GSK North American pharmaceuticals.
Insider's view: Great question from the FDA. Looks like they are getting their groove back!
No comments:
Post a Comment